Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2010

01-12-2010 | Guidelines

131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging

Authors: Emilio Bombardieri, Francesco Giammarile, Cumali Aktolun, Richard P. Baum, Angelika Bischof Delaloye, Lorenzo Maffioli, Roy Moncayo, Luc Mortelmans, Giovanna Pepe, Sven N. Reske, Maria R. Castellani, Arturo Chiti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2010

Login to get access

Abstract

The aim of this document is to provide general information about mIBG scintigraphy in cancer patients. The guidelines describe the mIBG scintigraphy protocol currently used in clinical routine, but do not include all existing procedures for neuroendocrine tumours. The guidelines should therefore not be taken as exclusive of other nuclear medicine modalities that can be used to obtain comparable results. It is important to remember that the resources and facilities available for patient care may vary from one country to another and from one medical institution to another. The present guidelines have been prepared for nuclear medicine physicians and intend to offer assistance in optimizing the diagnostic information that can currently be obtained from mIBG scintigraphy. The corresponding guidelines of the Society of Nuclear Medicine (SNM) and the Dosimetry, Therapy and Paediatric Committee of the EANM have been taken into consideration, and partially integrated into this text. The same has been done with the most relevant literature on this topic, and the final result has been discussed within a group of distinguished experts.
Literature
1.
Nakajo M, Shapiro B, Copp J, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-I123-iodobenzylguanidine (I-123 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983;24:672–82.PubMed
2.
Rubello D, Bui C, Casara D. Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002;147:13–28.CrossRefPubMed
3.
Leung A, Shapiro B, Hattner R, et al. The specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997;38:1352–7.PubMed
4.
Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999;43:217–23.PubMed
5.
Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 1987;15:170–7.CrossRefPubMed
6.
Bombardieri E, Maccauro M, De Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 2001;12:S51–61.CrossRefPubMed
7.
Troncone L, Rufini V. Radiolabeled metaiodobenzylguanidine in the diagnosis of neural crest tumors. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 1998. p. 843–57.
8.
Staalman CR, Hoefnagel CA. Imaging of neuroblastomas and metastasis. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, editors. neuroblastoma. Amsterdam: Elsevier; 2000. p. 303–29.
9.
International Commission on Radiological Protection. Publication 80: Radiation dose to patients from radiopharmaceuticals. Annals of the ICRP, vol. 28. Oxford: Pergamon Press; 1998. p. 3.
10.
Stabin MG, Gelfand MJ. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998;42:93–112.PubMed
11.
International Commission on Radiological Protection. Publication 53: Radiation dose to patients from radiopharmaceuticals. Annals of the ICRP, vol. 18. Oxford: Pergamon Press; 1987. p. 1–4.
12.
Boubaker A, Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med 2003;47:31–40.PubMed
13.
Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999;21:13–8.CrossRefPubMed
14.
Wafelman AR, Hoefnagel CA, Maes RA, et al. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interaction, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545–59.CrossRefPubMed
15.
Olivier P, Colarinha P, Fettich J, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003;30:B45–50.CrossRefPubMed
16.
Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F, EANM Dosimetry and Paediatrics Committees. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 2007;34:796–8.CrossRefPubMed
17.
Solanki KK, Bomanji J, Moyes J, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513–21.CrossRefPubMed
18.
Khafagi FA, Shapiro B, Fig LM, et al. Labetalol reduces iodine-131-MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481–9.PubMed
19.
Giammarile F, Boneu A, Edeline V, et al. Guide de réalisation de la scintigraphie à la meta-iodobenzylguanidine (MIBG) en oncologie pédiatrique. Med Nucl 2000;24:35–41.
20.
Sokole EB, Plachcinska A, Britten A. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010;37:662–71.CrossRef
21.
Meyer-Rochow GY, Schembri GP, Benn DE, Sywak MS, Delbridge LW, Robinson BG, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (mIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol 2010;17:392–400.CrossRefPubMed
22.
Rufini V, Fisher GA, Shulkin BL, et al. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996;37:1464–8.PubMed
23.
Rufini V, Giordano A, Di Giuda D, et al. 123MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 1995;4:25–8.
24.
Lynn MD, Shapiro B, Sisson JC, et al. Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication. J Nucl Med 1984;25(4):436–40.PubMed
25.
Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 1999;6(3):119–24.CrossRefPubMed
26.
Okuyama C, Sakane N, Yoshida T, Shima K, Kurosawa H, Kumamoto K, et al. (123)I- or (125)I-metaiodobenzylguanidine visualization of brown adipose tissue. J Nucl Med 2002;43(9):1234–40.PubMed
27.
Peggi L, Liberti E, Pansini G, et al. Pitfalls in scintigraphic detection of neuroendocrine tumors. Eur J Nucl Med 1992;19:214–8.
28.
Gordon I, Peters AM, Gutman A, et al. Skeletal assessment in neuroblastoma – the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990;31:129–34.PubMed
29.
Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, et al. A new 123I-MIBG whole body scan scoring method – application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995;31A(2):256–61.CrossRefPubMed
30.
Suc A, Lumbroso J, Rubie H, Hattchouel JM, Boneu A, Rodary C, et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996;77(4):805–11.CrossRefPubMed
31.
Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M, et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004;22(19):3909–15.CrossRefPubMed
32.
Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47(7):865–74.CrossRefPubMed
33.
Taal BG, Hoefnagel CA, Valdes Olmos, et al. Combined diagnostic imaging with 131I-MIBG and 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996;32:1924–32.CrossRef
34.
Zuetenhorst JM, Hoefnagel CA, Boot H, et al. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002;23:735–41.CrossRefPubMed
35.
Adams S, Baum R, Rink T, et al. Limited value of fluorine-18fluoodeoxyglucose PET for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79–83.CrossRefPubMed
36.
Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (mIBG) scan and [18F]FDG positron emission tomography to evaluate response after iodine-131 mIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009;27:5343–49.CrossRefPubMed
37.
Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397–405.PubMed
38.
Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S. 123I-mIBG versus 18F-FDG in neuroblastoma: which is better, or which can be eliminated? J Nucl Med 2010;51:331.CrossRef
39.
Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-mIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237–43.CrossRefPubMed
40.
Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-l-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-mIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009;94:4757–67.CrossRefPubMed
41.
Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol 1992;65:787–91.CrossRefPubMed
Metadata
Title
131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging
Authors
Emilio Bombardieri
Francesco Giammarile
Cumali Aktolun
Richard P. Baum
Angelika Bischof Delaloye
Lorenzo Maffioli
Roy Moncayo
Luc Mortelmans
Giovanna Pepe
Sven N. Reske
Maria R. Castellani
Arturo Chiti
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1545-7

Other articles of this Issue 12/2010

European Journal of Nuclear Medicine and Molecular Imaging 12/2010 Go to the issue

Editorial Commentary

Coronary endothelial function: a clinical role for PET?

Society communications

The EANM scientific pillars – the EANM proudly presents its 11 committees

Original Article

Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275

Original Article

99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres

Erratum

Erratum to: Three-dimensional echocardiography and 153Sm-EDTMP-SPECT/CT in extensive cardiac metastases from osteosarcoma

Original Article

Detection of respiratory tumour motion using intrinsic list mode-driven gating in positron emission tomography